 | Up a level |
Gautschi, O.; Mach, N.; Rothschild, S.; Li, Qiyu; Stahel, R. A.; Zippelius, A.; Cathomas, R.; Früh, M.; Betticher, D. C.; Peters, S.; Rauch, D.; Feilchenfeldt, J.; Bubendorf, L.; Savic, S.; Jaggi, Rolf; Oppliger Leibundgut, Elisabeth; Largiadèr, Carlo Rodolfo; Brutsche, M.; Pilop, C.; Stalder, L.; ... (2015). Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clinical lung cancer, 16(5), pp. 358-365. Elsevier 10.1016/j.cllc.2015.02.007
Jermann, M.; Jost, L. M.; Taverna, Ch.; Jacky, E.; Honegger, H. P.; Betticher, D. C.; Egli, F.; Kroner, Th.; Stahel, R. A. (2004). Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Annals of oncology, 15(3), pp. 511-516. Oxford University Press 10.1093/annonc/mdh093
Rosell, R.; Gatzemeier, U.; Betticher, D. C.; Keppler, U.; Macha, H. N.; Pirker, R.; Berthet, P.; Breau, J. L.; Lianes, P.; Nicholson, M.; Ardizzoni, A.; Chemaissani, A.; Bogaerts, J.; Gallant, G. (2002). Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of oncology, 13(10), pp. 1539-1549. Oxford University Press 10.1093/annonc/mdf332
Tschan, Mario; Peters, U. R.; Cajot, J. F.; Betticher, D. C.; Fey, M. F.; Tobler, A. (1999). The cyclin-dependent kinase inhibitors p18INK4c and p19INK4d are highly expressed in CD34+ progenitor and acute myeloid leukaemic cells but not in normal differentiated myeloid cells. British journal of haematology, 106(3), pp. 644-651. Wiley-Blackwell 10.1046/j.1365-2141.1999.01617.x
Betticher, D. C.; Ratschiller, D.; Hsu Schmitz, S.-F.; Von Rohr, A.; Hess, U.; Zulian, G.; Wernli, M.; Tichelli, A.; Tobler, A.; Fey, M. F.; Cerny, T. (1998). Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Annals of oncology, 9(7), pp. 721-726. Oxford University Press 10.1023/A:1008273131598
Betticher, D. C.; Zucca, E.; Von Rohr, A.; Egger, T.; Radford, J. A.; Ambrosetti, A.; Bürki, K.; Rufener, B.; Hsu Schmitz, S. F.; Cerny, Thomas (1996). 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III–IV non-Hodgkin's lymphoma. Annals of oncology, 7(8), pp. 793-799. Oxford University Press 10.1093/oxfordjournals.annonc.a010757
Betticher, D. C.; Nicole, A.; Pugin, P.; Regamey, C. (1990). The Hyperreactive Malarial Splenomegaly Syndrome in a European: Has the Treatment a Modulatory Effect on the Immune System? Journal of infectious diseases, 161(1), pp. 157-159. The University of Chicago Press 10.1093/infdis/161.1.157
